Published on : Nov 21, 2017
ALBANY, New York, November 21, 2017: The report studies every facet of the market to uncover its overall revenue, size, competitive dynamics, and growth prospects, going forward. It carefully examines the growth drivers and trends shaping the trajectory of the market. The aim is to help stakeholders gather a thorough understanding about the current trends and vulnerabilities of the market so as to enable them to take carefully-considered decisions.
Monoclonal antibodies (mAbs) are a collection of antibodies composed of similar immune cells that are all clones of a unique parent cell. They are complex proteins with high molecular weight. These proteins are classified as humanized, chimeric, and fully human and find frequent application in targeted therapies such as antibody-directed enzyme prodrug therapy and radioimmunotherapy. They are also useful in drug development.
Monoclonal antibodies (mAbs), developed in the mid-1970s, can be produced against any given substance. Already a considerable number of mAb products are being purveyed in the market. However, most of them are still in the early-stages of development, which indicates potential products would be launched after some time. Despite this, mAbs gross maximum revenue in the pharmaceutical sector and is expanding at healthy clip.
At present, around 2,836 mAbs are in the pipeline. Majority of them are in early stages of development, with a substantial 76.0% at the discovery or preclinical stage. In addition, there are 85 mAb programs in Phase III development at present, and another 22 in the pre-registration stage. They account for just under 4% of the total mAb pipeline.
Get SAMPLE REPORT PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1362755
Majorly fuelling the global monoclonal antibodies market is the rising instances of cancer and other chronic diseases. They have driven up demand for biologics, which in turn is driving demand for monoclonal antibodies. Exhaustive research and development activities in genomics coupled with evermore technologically advanced genetic platforms, such as next generation sequencing, have also been positively impacting the market. Increasing knowledge among physicians and patients about advantages of mAb therapy, frequent products launches, increasing uptake of therapeutic antibodies in cost-sensitive markets, and quick approval by regulatory authorities for innovative therapies are fuelling the market too.
In the near future, rapid approvals of blockbuster mAbs for various indications, is expected to boost their usage. For example, FDA approval of popular drugs such as Avastin, Herceptin, Rituxan, and Remicade for treating Crohn's disease, rheumatoid arthritis, cancer, ulcerative colitis, etc. would benefit the market.
Posing a challenge to the monoclonal antibodies market is the fact that drugs formulated from them are highly specific in nature and have limited targets since they simply interact with the cells and do not penetrate them. Another challenge is that mAbs need to be injected unlike small molecule drugs.
Geographically, the key segments of the global monoclonal antibodies market are Asia Pacific, Europe, North America, and the Rest of the World. North America, of them, leads the market due to the presence of a superior healthcare infrastructure, thrust by the government on control and management of infection, and increasing prevalence of lifestyle-related diseases. In the foreseeable future too, the market will continue progressing on the back of funding by the government for cancer research and technology development.
Some of the prominent names operating in the global market for monoclonal antibodies profiled in the report are Roche, Genentech, Eli Lilly, Pfizer, and Biogen Idec.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]